Patient P-01321
Therapy response
Stable
Tolerance
Deteriorating
GI state
Deteriorating
Inflammatory state
Deteriorating
Nutritional resilience
Declining
Discontinuation risk
44%
Trajectory
Baseline → today → 30-day prediction · hover a day for signals and eventssolid = observed · dashed = predicted
- Day 0 NBL-101 started — Baseline state S12
- Day 81 Trajectory diverged from prediction — Observed response fell below the model's expected path.
- Day 82 GI-04 recommended — GI Support Protocol GI-04
- Day 83 Patient accepted — Started GI-04 in the companion
- Day 91 GI symptom burden −24% vs expected — GI Support Protocol GI-04
- Day 97 Tolerance state changed — Unstable → Improving
What changed?
Trajectory began diverging from predicted response on Day 81.
Primary contributors, last 14 days
- Nutritional resilience-11
- Toxicity+9
- GI instability+6
- Inflammatory activity+5
- Treatment adherence-2
What helped?
- GI Support Protocol GI-04Day 82Result: symptom burden −24%
LIFE OS recommendation
Dietary Support Protocol NP-02
65%
probability of meaningful tolerance improvement
- 284 similar trajectories
- 100% showed improvement
- median effect visible after 10 days
Biological layers
Which pathways look influenced, and by which layer of this person's biology.
Pathways under pressure
- Butyrate / short-chain fatty acid production ↓80
- MicrobiomeButyrate capacity 44/100
- MicrobiomeF. prausnitzii depleted
- Daily logFibre intake low in recent food logs
- Mucosal barrier integrity ↓70
- DNAFUT2 non-secretor lowers mucosal fucosylation
- MicrobiomeAkkermansia low → thinner mucus layer
- WearableSleep 5.3 h, below personal baseline
- Inflammatory signalling ↑45
- MicrobiomeBacteroides fragilis expansion
- BloodInflammatory load index 48
- Drug metabolism and exposure ↑20
- BloodToxicity index 41
- Autonomic recovery ↑20
- WearableShort sleep window
DNA
Fictional pharmacogenomic panel
- FUT2 rs601338 AA (non-secretor)Reduced mucosal fucosylation
- CYP2D6 Intermediate metabolizerExpected exposure
- MTHFR C677TReduced folate turnover
Microbiome
Shannon diversity 3 · butyrate capacity 44/100
- Akkermansia muciniphilaLow
- Faecalibacterium prausnitziiLow
- Bacteroides fragilisHigh
- Bifidobacterium longumLow
- EnterobacteriaceaeHigh
Wearable, last 14 days
daily evolution fed into the runtime
- HRV
- 61 ms
- Sleep
- 5.7 h
- Steps
- 6,832
- Resting HR
- 65 bpm
Daily log: GI score 41, nutritional resilience 43, adherence 84.
What this patient sees in NostraAI
The content that steers the trajectory: what to eat, what to do, what to take.
What to eat
- Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
- Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
- Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
- Avoid known triggers for now: fried or oily food, dairy, alcohol
What to do
- Track each bowel movement today: time, stool form, urgency, overnight waking
- Keep the current walking rhythm
- Protect a 7.5-hour sleep window; screens off 30 minutes before
- Keep hydration steady: small amounts through the day rather than large volumes at once
What to take
- Take the scheduled dose as agreed with your care team
- Electrolyte solution, one sachet after any loose stool
- Fictional demo item: oral nutrition supplement with lunch
284 biologically similar trajectories
Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.